October 2022—Mdxhealth has entered into a purchase agreement with Genomic Health, a subsidiary of Exact Sciences, to acquire Exact Sciences’ Oncotype DX Genomic Prostate Score test and most of the company’s team of urology sales and marketing professionals.
Under the terms of the asset purchase agreement, Mdxhealth acquired the Oncotype DX GPS prostate cancer business for an aggregate purchase price of up to $100 million.
MDxhealth, 949-812-6979